SEC Form 4 · accession 0001209191-16-111851
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanjay Shukla
Officer — Chief Medical Officer
Period of report
Mar 30, 2016
Accepted (ET)
Apr 1, 2016 · 8:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $4.86 | Mar 30, 2016 | A | 163,000 | A | — | Mar 30, 2026 | Common Stock | 163,000 | 163,000 | D |
Explanation of responses
- F11/4th of the shares subject to this option shall vest and become exercisable on March 30, 2017 and the remaining shares subject to this option shall vest and become exercisable in 36 equal monthly installments, such that this option is fully exercisable on March 30, 2020. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.